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Background: In computed tomography lung cancer screening pro-
grams, up to 30% of all resections are futile.
Objective: To investigate whether a preoperative positron emission
tomography (PET) after a conclusive or inconclusive nonsurgical
workup will reduce the resection rate for benign disease in test-
positive participants of a lung cancer screening program.
Methods: (18)F-Fluorodeoxyglucose-PET scans were made in
220 test positives. Nodules were classified as positive, indeter-
minate, or negative based on visual comparison with background
activity. Gold standard for a positive PET was the presence of
cancer in the resection specimen or the detection of cancer during
more than 2 years follow-up. Sensitivity, specificity, positive
predictive value, and negative predictive value (NPV) were
calculated at participant level and 95% confidence intervals (CIs)
constructed.
Results: The sensitivity of PET to detect cancer was 84.2% (95%
CI: 77.6 –90.7%), the specificity 75.2% (95% CI: 67.1–83.3), the
positive predictive value 78.9% (95% CI: 71.8 –86.0), and the
NPV 81.2% (95% CI: 73.6 –88.8). The resection rate for benign
disease was 23%, but 26% of them had a diagnosis with clinical
consequences. A preoperative PET after an inconclusive nonsur-
gical workup reduced the resection rate for benign lesions by 11
to 15%, at the expense of missing 12 to 18% lung cancer cases.
A preoperative PET after a conclusive nonsurgical workup re-
duced the resection rate by 78% at the expense of missing 3%
lung cancer cases.
Conclusion: A preoperative PET scan in participants with an
inconclusive nonsurgical workup is not recommended because of
the very low NPV, but after a conclusive nonsurgical workup, the
resection rate for benign disease can be decreased by 72%.
Key Words: Positron emission tomography, PET scan, Pulmonary
nodule, Benign nodule, Lung cancer, Thoracic surgery.
(J Thorac Oncol. 2011;6: 1704–1712)
The utility of low-dose multidetector low-dose computedtomography (CT) screening is being investigated in sev-
eral nonrandomized1–5 and randomized trials.6–9 Two large
randomized screening trials investigate whether CT screening
leads to a reduction in lung cancer mortality. The largest one,
the National Lung Screening Trial has randomized 53,476
smokers between annual CT screening or chest x-ray for three
annual screening rounds.6 The “Nederlands Leuvens Long-
kanker Screenings Onderzoek” (NELSON) is the second
largest randomized lung cancer screening trial in which CT
screening in year 1, 2, 4, and 6.5 is compared with a control
population without screening. The nodule management strat-
egy used in the NELSON trial is based on the volume of new
noncalcified nodules and the volume doubling time (VDT) of
previously existing ones, without need for additional evalu-
ations by fine needle aspirate, positron emission tomography
(PET), or radiological evaluation after antibiotics.10 As a
result of this management strategy, 27% and 19% of the
surgical resections performed at baseline and second round
screening, respectively, have been performed for benign dis-
ease.7 Question is, whether a PET scan could be used to
reduce the resection rate for benign disease in a lung cancer
screening setting.
The purpose of this study was to investigate whether a
preoperative PET after either an inconclusive or a conclusive
nonsurgical workup, which included a physical examination,
standard CT with contrast, and a bronchoscopy, will reduce
the resection rate for benign disease.
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METHODS AND MATERIALS
Study Population
NELSON trial participants were current and former
smokers at high risk for lung cancer. Detailed information on
the inclusion and exclusion criteria has been reported be-
fore.11 The prospective screening study was approved by the
Dutch Minister of Health and by the Medical Ethical Boards
of each of the four participating hospitals. Written informed
consent was obtained from all participants, which included
the ability to use data for future research, including the
current prospective side study. In this study, participants have
been included with a positive baseline or second round test
result between April 2004 and October 2008.
CT Data Acquisition and Image Reading
Data acquisition and image reading were as described
before.10 In brief, all four participating screening sites used
16-detector CT scanners (Sensation-16, Siemens Medical
Solutions, Forchheim, Germany Mx8000 IDT or Brilliance
16P, Philips Medical Systems, Cleveland, OH). Scan data
were obtained in a spiral mode, with 16  0.75 mm colli-
mation and 1.5 pitch. No contrast was administered. Data
acquisition and scanning conditions were standardized and
equal for baseline and repeat screening. Digital worksta-
tions (Leonardo, Siemens Medical Solutions, Erlangen,
Germany) were used in all screening sites with commer-
cially available software for semiautomated volume mea-
surements (LungCare, Siemens Medical Solutions, version
Somaris/5: VA70C-W).12,13
Nodule Management and Diagnostic Workup
At baseline, a scan was considered positive if any
noncalcified nodule had a solid component more than 500
mm3 (9.8 mm in diameter) or indeterminate if the volume
of the largest solid nodule or the solid component of a
partially solid nodule was 50 to 500 mm3 (4.6–9.8 mm in
diameter) or more than 8 mm in diameter for nonsolid
nodules.10 Subjects with an indeterminate result had a fol-
low-up scan 3 months later to assess growth. Significant
growth was defined as a change in volume between the first
and second scan of 25%. Subjects with positive screening
tests were referred to a chest physician for workup and
diagnosis.7 If lung cancer was diagnosed, the participant was
treated for the disease and went off screening; if no lung
cancer was found, the regular second round CT scan was
scheduled 12 months after the baseline scan.
For participants with one or more new nodules on the
second round scan, the result (positive or negative) was based
on size of the nodule, as for round one; in case of an
indeterminate result, a follow-up scan was performed 6
weeks later.10 For participants with previously detected nod-
ules, the second round result was based on the VDT. If there
was no growth or if the VDT was more than 600 days, the
screen was declared negative.7 If the VDT was less than 400
days or if a new solid component had emerged in a previously
nonsolid nodule, the scan was considered to be positive.
When the VDT was 400 to 600 days, the test was indetermi-
nate, and a follow-up scan was done 1 year after the second
round. With a VDT less than 400 days, the final result was
considered to be positive, otherwise negative. If both new
and existing nodules were present, the nodule with the
largest volume or fastest growth determined the result. All
participants with a negative second round result were
invited to undergo the third screening round 2 years after
the second round.
Workup and staging were standardized for all screening
sites according to (inter-) national guidelines and included a
physical examination, a standard CT scan with contrast of the
chest and upper abdomen, a bronchoscopy, and (18)F-fluo-
rodeoxyglucose-PET (FDG-PET).10,14,15 After a negative
nonsurgical workup, subjects were referred for surgery to
obtain histology of the suspicious nodule. Bronchoscopies
were done for the evaluation of the central airways and (if
possible) to diagnose lung cancer or benign disease. PET
scans were made for preoperative staging purposes in cases
the nodule turned out to be malignant during surgery. Pul-
monologists were not blinded to the PET result. Therefore,
PET results may have influenced the decision to resect
nodules, although the NELSON protocol asked for resection
irrespective of the outcome of the PET scan. National and
international pathology review panels evaluated all cytolog-
ical and histological specimens. A procedure was classified as
surgical if it was a mediastinoscopy, video-assisted thoracos-
copy (VATS), or thoracotomy. Resections for benign disease
were in this study limited to thoracotomies or VATS proce-
dures for benign lung lesions.16,17 A clinical relevant benign
diagnosis was defined as a new benign diagnosis that influ-
enced subsequent patient management, including medication
and/or treatment changes.
(18)F-Fluorodeoxyglucose-PET
Data acquisition.
FDG-PET scans were performed by Siemens ECAT
ACCEL PET (Haarlem), Siemens ECAT EXACT PET 962
(Groningen), Siemens Biograph 2-slice PET/CT (Haarlem,
Leuven), and Philips Allegro PET scanner (Utrecht). Each of
the four centers used different FDG-PET protocols. All pa-
tients were asked to fast for at least 6 hours before the
PET/CT scan. After administering 300 to 400 MBq radio-
tracer, the images were obtained. The uptake time after
injection of FDG was standard for each center (90 minutes for
Groningen and 60–75 minutes in the other centers). The PET
data were acquired in three-dimensional mode (Leuven,
Haarlem) and 2D mode (Groningen, Utrecht). PET-acquisi-
tion time was 4 to 5 minutes per table position, with a
complete scan time of approximately 30 minutes. The whole-
body (CT) PET extended from the head to the upper tights.
PET images were reconstructed by the ordered subset expec-
tation maximization algorithm, with attenuation correction in
all centers, with the exception of Utrecht where Row Action
Maximum Likelihood Algorithm was used. No respiratory
gating was used.
Data processing.
Standard uptake values (SUV) have not been used
because different PET cameras were used, and no standard
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reference values were available.18 At each institution, the
nuclear physicians used always the same work stations (Di-
com or Siemens work station) at standard settings. FDG-PET
scans were classified as positive, indeterminate, or negative
based on visual comparison with the background activity
after single reading at each of the four centers. The FDG-PET
results were matched with the suspicious nodule on CT or, in
case no nodules were present, a pulmonary mass (3 cm in
diameter), a (postobstructive) infiltrate, or an atelectatic area.
Data Analysis
For this retrospective analysis, the sensitivity, specific-
ity, positive predictive value (PPV), and negative predictive
value (NPV) of FDG-PET was calculated for four different
groups; all participants with a positive baseline or second
round test result; participants with a negative noninvasive
workup; participants with a positive test result and a suspi-
cious nodule more than 500 mm3; and participants with a
positive test result and a suspicious nodule with a VDT less
than 400 days. In the first analysis, PET positive and inde-
terminate test results were taken together and considered PET
positive, in the second analysis PET indeterminate and neg-
ative results were taken together and considered PET nega-
tive. Gold standard for the outcome of FDG-PET was the
pathological diagnosis of the suspicious lesion or if no sur-
gical resection was performed, the presence or absence of
cancer during at least 2 years of follow-up. If a subject was
diagnosed with lung cancer after an initial benign diagnosis
and the interval between the first PET scan and the second
workup was more than 200 days, this new cancer was not
included in the calculation of the diagnostic value of PET
because of the long time interval; 95% confidence intervals
(CIs) were constructed by SPSS software package version
15.0. In the absence of normal distribution, data were pre-
sented as medians with a range.
RESULTS
Participant and Nodule Characteristics
In total, 324 subjects had a positive test result after
baseline and second round screening. Their median age was
62 years (range: 50–75 years), the median number of pack-
years smoked was 43 (range: 21–160 pack-years), and 20%
were women. The characteristics of the suspicious nodules
detected in these test-positive participants are listed in Table
1. In 95 test-positive participants, no PET scan was made: 29
were not referred for workup, and in 66 participants (55 
11), this was a tumor board decision (Figure 1). Nodule size
was significant larger in the group who underwent a PET
scan, but there were no significant differences in VDT or
nodule consistency between the two groups. The mean nod-
ule size of the 293 solid nodules was 648 mm3 (28–5486
mm3), of the 16 nodules with mixed attenuation 526 mm3
(169–4610 mm3), and of the four pure ground-glass nodules
452 mm3 (135–638 mm3).
Nonsurgical Workup
In total, 240 test-positive participants were referred to a
chest physician for nonsurgical workup, which included a
bronchoscopy and a standard dose CT with contrast. The
diagnostic procedures performed during bronchoscopy were
washings (65%), brushings (25%), endobronchial biopsies
(7%), transbronchial biopsies (3%), and transbronchial punc-
tions (1%) but no lavages. The role of bronchoscopy and CT
scan with intravenous contrast made during evaluation by the
pulmonologist will be described separately. In 93 partici-
pants, nonsurgical workup was conclusive and in 147 incon-
clusive. In case of regression or disappearance of a nodule on
CT with intravenous contrast, the workup was terminated and
considered as benign. All 147 subjects with an inconclusive
nonsurgical workup were referred for surgery (Figure 1).
Surgical Workup
In 11 of 147 participants with an inconclusive nonsur-
gical workup, no PET scan was made (tumor board decision).
In 46% (5/11), these resections were done for benign disease;
in one of them (1/5), the diagnosis had clinical consequences
(Langerhans cell histiocytosis) (Figure 1). The remaining 136
patients underwent a PET scan and were subsequently oper-
ated upon. Twenty-three percent (31/136) of these resections
were done on benign nodules (Figure 1). In these 31 patients,
five VATS procedures and 26 thoracotomies (15 wedge
resections, seven lobectomies, and four histological true-cut
biopsies) have been performed. Twenty-six percent (8/31) of
the resections for benign disease had clinical consequences
with respect to follow-up or initiation of treatment and
included latent tuberculosis (2), active tuberculosis (1), asper-
gilloma (2), tumorlet (2), and atypical adenomatous hyper-
TABLE 1. Characteristics of the Suspicious Nodules in 324
Test-Positive Participants of the NELSON Lung Cancer
Screening Trial
FDG-PET (%),
N  229
No
FDG-PET (%),
N  95 pa
Nodule size
50 mm3 (4.6 mm) 3 (1) 2 (2)
50–500 mm3 (4.6–9.8 mm) 64 (28) 37 (39)
500 mm3 (9.8 mm) 159 (70) 48 (50) 0.001
NAb 3 (1)b 9 (9)c
Volume doubling time (VDT)
VDT 600 d 7 (3) 7 (7)
VDT 400–600 d 4 (2) 3 (3)
VDT 400 d 96 (42) 31 (32) 0.53
NAd 122 (53) 55 (57)
Nodule consistency
Solid 212 (93) 81 (84)
Part solid 13 (6) 3 (3)
Ground glass 1 (0) 3 (3) 0.23
Not specified 3 (1) 9 (10)
a Fisher’s exact test.
b No nodules (n  3): multiple metastasis (1 subject), atelectasis (1), and consol-
idation (1).
c No nodules (n  9): Langerhans histiocytosis (1 subject), atelectasis (3), consol-
idation (3), pleural fluid (1), and mediastinal mass (1).
d Calculation VDT not possible (n  177): baseline nodules (116), new nodules
(55), and no nodules (6).
NA, not available; FDG-PET, (18)F-fluorodeoxyglucose-positron emission tomography.
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plasia (1). Nine subjects were diagnosed with malignancies
other than lung cancer after surgery: pulmonary metastasis
from colon (3), prostate (2), oral cavity (1), esophagus (1), a
thymoma, and maltoma of the lung (Figure 1).
FDG-PET Performance
The median time between PET and surgery was 28 days
(range: 5–203 days). In Tables 2 and 3, the lung cancer
diagnoses and nodule characteristics are presented. Of the
109 lung cancers detected, 17% was PET negative, 79%
positive, and 4% indeterminate (Table 3). Of the PET posi-
tive, negative, and indeterminate lung cancers, 20%, 53%,
and 17%, respectively, was less than 500 mm3. The one pure
ground-glass nodule was PET negative and the four partial
solid lesions PET positive, except for the carcinoid, which
was PET negative.
For all test-positive subjects (n  229), the sensitivity,
specificity, PPV, and NPV of PET was 84%, 75%, 79%, and
81%, respectively, when the indeterminate test results were
considered PET positive. In 25% (27/109), PET was false
positive (Table 4). When the indeterminate test results were
considered PET negative, the sensitivity, specificity, PPV,
and NPV were 77%, 88%, 88%, and 77%, respectively. In
12% (13/109), PET was false positive (Table 4). During
follow-up, eight subjects were diagnosed with lung cancer
after an initial negative workup during baseline or second
round screening (Table 5). The median time interval between
FIGURE 1. Overview of subjects with a positive screening result after baseline and second round screening with respect to
type of workup and outcome of (18)F-fluorodeoxyglucose-positron emission tomography (FDG-PET).
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the first and second workup was 716 days (259–974 days).
Based on this retrospective information, the sensitivity, spec-
ificity, PPV, and NPV of the initial PET were 80%, 75%,
80%, and 75%, respectively, when the indeterminate test
results were considered PET positive. When the most recent
PET was taken, these values were 84%, 75%, 81%, and 78%,
respectively.
The role of PET was also investigated for all test-
positive subjects in whom the suspicious nodule was larger
than 500 mm3 (9.6 mm in diameter) (n  156); these data
are presented in Table 4.
Finally, we investigated the role of a preoperative PET
in 137 patients who underwent surgical resection of the
suspicious nodule after an inconclusive nonsurgical workup.
TABLE 2. Histological Diagnoses, FDG-PET Result, and Nodule Characteristics of the 32 Subjects Who
Underwent Surgery for Benign Disease during Baseline and Second Round Screening of the NELSON Lung
Cancer Screening Trial
No.
Histological
Diagnosis PET
Maximum
Diameter (mm) Consistency
Volume Doubling
Time (d)
Benign/normal tissue
1 Lymph node Negative 6 Solid 400
2 Lymph node Negative 8 Solid 400
3 Lymph node Negative 6 Solid 400
4a Lymph node with
sinus histiocytosis
Indeterminate 16 Solid 400
5 Lymph node Positive 15 Solid 400
6 Lymph node Negative 12 Solid 400
7 Lymph node Negative 6 Solid 400
8 Hamartoma Negative 11 Solid New nodule
9 Hamartoma Negative 12 Solid New nodule
10 Hamartoma Negative 7 Solid 400
11 Hamartoma Indeterminate 16 Solid New nodule
12 Infarction Indeterminate 8 Solid 400–600
13 Infarction Negative 15 Solid New nodule
14 Infarction Indeterminate 33 Solid New nodule
15 Infarction Positive 17 Solid New nodule
16 Fibrosis Positive 29 Solid New nodule
17 Focal organizing
pneumonia
Indeterminate 13 Solid New nodule
18 Pulmonary apical cap Positive 15 Solid 400
19 Mixed papilloma Negative 10 Solid 400
Infectious/inflammatory
nodules
20 Granuloma and
necrosis
Positive 13 Solid New nodule
21 Granuloma and
necrosis
Positive 12 Solid New nodule
22 Granuloma and
necrosis
Negative 8 Solid 400
23 Granuloma Negative 10 Solid 400
24 Granuloma Negative 9 Solid 400
25 Organizing pneumonia Positive 17 Solid New nodule
26 Organizing pneumonia Positive 11 Solid 400
27 Aspergilloma Positive 14 Solid 400
28 Aspergilloma Negative 17 Solid New nodule
29 Lymphoid hyperplasia Indeterminate 14 Solid New nodule
Preinvasive lesions
30 Tumourlet Positive 21 Solid 400
31 Tumourlet Negative 9 Solid 400
32 Atypical adenomatous
hyperplasia
Positive 34 partial-solid New nodule
a No histology obtained of suspicious nodule, mediastinoscopy only, and the 2 yr follow-up period was eventless.
FDG-PET, (18)F-fluorodeoxyglucose-positron emission tomography.
van’t Westeinde et al. Journal of Thoracic Oncology • Volume 6, Number 10, October 2011
Copyright © 2011 by the International Association for the Study of Lung Cancer1708
The sensitivity, specificity, PPV, and NPV were 85%, 47%,
84%, and 48%, respectively, when the indeterminate test
results were considered PET positive (Table 4). When the
indeterminate test results were considered PET negative, the
sensitivity, specificity, PPV and NPV were 77%, 66%, 88%,
and 47%, respectively (Table 4).
DISCUSSION
In this study, we evaluated the role of PET in 229
subjects with a positive baseline or second round test result.
The prevalence of cancer in this population was 52%. The
sensitivity of PET to detect cancer 84.2% (95% CI: 77.6–
90.7%), the specificity 75.2% (95% CI: 67.1–83.3), the PPV
78.9% (95% CI: 71.8–86.0), and the NPV 81.2% (95% CI:
73.6–88.8). For subjects with nodules larger than 500 mm3,
the sensitivity was 90.9% (95% CI: 84.9–96.6%), the speci-
ficity 66.2% (95% CI: 55.2–77.2%), the PPV 76.9% (68.8–
85.0%), and the NPV 85.5% (95% CI: 76.1–94.8%). The
resection rate for benign lesions was 23%; a preoperative
PET after an inconclusive nonsurgical workup reduced the
futile resection rate with 11 to 15%, at the expense of missing
12 to 18% lung cancer cases. A preoperative PET after a
conclusive nonsurgical workup reduced the futile resection
rate by 78% at the expense of missing 3% lung cancer cases.
Several investigators evaluated the role of PET in a
lung cancer screening setting. FDG-PET was part of their CT
screening protocol for nodules 7 mm (4), more than 8 mm,
and growing nodules less than 8 mm19 or nodules 10 mm
and growing nodules more than 7 mm.20 Pastorino et al.4
reported on the results of 42 PET scans, Bastarrika et al.20 on
25, and Veronesi et al.19 on 157 PET scans. Sensitivities and
specificities of PET in these settings ranged between 69 to
90% and 81 to 93%, respectively.4,19,20 They concluded that
a combination of CT and PET effectively detects lung cancer
and may help to reduce unnecessary surgeries for benign
lesions4,19,20 Veronesi et al.19 reported an overall specificity
of 93% for PET but with a wide range between 68% and
100%. For nodules 10 mm, the sensitivity was 91% at a
specificity of 68%. The other two authors did not report on
the value of PET in larger nodules only. Also, Lindell et al.21
investigated the role of PET. They found that 32% of the lung
cancers were PET negative. This might be due to the fact that
they are usually smaller (mean size 10 mm) and/or low-grade
lung cancers.21 Our false-negative lung cancers rate was with
16% lower, probably because the median nodule size of all
cancers detected was above 14 mm (Table 3). The overall
sensitivity in our study was comparable with the aforemen-
tioned studies,4,19,20 but the specificity was lower. For nodules
9.6 mm, however, our results are comparable with those
reported by Veronesi et al. for nodules 10 mm.
Question is whether the sensitivities and specificities of
PET found in lung cancer screening setting differ from
nonscreening series. Wahidi et al.22 reviewed 17 studies on
PET for the evaluation of solitary pulmonary nodules. The
TABLE 3. Histological Diagnoses, FDG-PET Result, and Nodule Characteristics of 109 Subjects Diagnosed with Lung Cancer
during Baseline and Second Round Screening of the NELSON Lung Cancer Screening Trial
No.
Histological
Diagnosis PET (%)
Median Diameter
(mm, Range) Consistency (%)
Volume Doubling
Time (d)a
58 Adenocarcinoma Positive 46 (79) 14 (5–68) Solid 53 (95)b VDT 600 3 (11)
Indeterminate 4 (7) Part solid 3 (5) VDT 400–600 3 (11)
Negative 8 (14) Ground glass 0 VDT 400 22 (78)
20 Large cell carcinoma Positive 17 (85) 18 (6–45) Solid 20 (100) VDT 600 0
Indeterminate 1 (5) Part solid 0 VDT 400—600 0
Negative 2 (10.0) Ground glass 0 VDT 400 7 (100)
16 Squamous cell
carcinoma
Positive 14 (88) 19 (7–47) Solid 15 (94) VDT 600 0
Indeterminate 1 (6) Part solid 1 (6) VDT 400–600 0
Negative 1 (6) Ground glass 0 VDT 400 8 (100)
6 Bronchoalveolar cell
carcinoma or
adenocarcinoma
with BAC features.
Positive 2 (33) 13 (9–22) Solid 5 (83) VDT 600 1 (20)
Indeterminate 0 (0) Part solid 0 (17) VDT 400—600 0
Negative 4 (67) Ground glass 1 (17) VDT 400 4 (80)
3 Carcinoid Positive 1 (33) 17 (13–20) Solid 2 (67) VDT 600 0
Indeterminate 0 (0) Part solid 1 (33) VDT 400–600 0
Negative 2 (67) Ground glass 0 VDT 400 1 (100)
2 Small cell lung
cancer
Positive 2 (100) 15 (15–15) Solid 2 (100) VDT 600 0
Indeterminate 0 Part solid 0 VDT 400–600 0
Negative 0 Ground glass 0 VDT 400 1 (100)
4 Diagnosis lung
cancer, no
cytology/histology
Positive 4 (100) 20 (12–21) Solid 4 (100) VDT 600 1 (100)
Indeterminate 0 Part solid 0 VDT 400–600 0
Negative 0 Ground glass 0 VDT 400 0
aNumbers do not add up because for baseline and new nodules no VDT can be calculated.
bNumbers do not add up to 58 because one subject had a postobstruction infiltrate and no nodules on CT.
FDG-PET, (18)F-fluorodeoxyglucose-positron emission tomography; VDT, volume doubling time; CT, computer tomography.
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median specificity in these studies was 82.6% (range: 40–
100%), with a corresponding sensitivity of 87% (range:
80–100%). In a meta-analysis of 40 studies on pulmonary
nodules and mass lesions, a sensitivity of 97% at a specificity
of 83.3% was found.23 The sensitivities and specificities in a
lung cancer screening setting are thus slightly lower than in a
nonscreening setting, most likely because of smaller tumor
sizes, differences in the a priori lung cancer probability, and
distribution in tumor histology in lung cancer screening.
When the use of PET was limited in our study to subjects
with suspicious nodules 500 mm3 (9.6 mm), the speci-
ficity remained very low with only a slight increase in
sensitivity. This can be explained by the fact that many of the
new and growing nodules 500 mm3 and with a VDT less
than 400 days were false PET positive and represent enlarged
lymph nodes, hyperplastic lymphoid tissue, or granulomas.
In a multidetector CT lung cancer screening setting, the
resection rate for benign lesions at baseline varied between
0% and 43% with a median value of 19%,3–5,8,9,20,24–30 This
demonstrates that by using the NELSON nodule management
strategy, in which the number of recall CT scans was strictly
limited to only 1 per screening round and in which volumetric
software evaluation replaced FNA, PET, or evaluations after
antibiotics, similar resection rates for benign disease were
found in comparison with the literature.10 Although there is
no consensus what an acceptable resection rate for benign
lesions is, a rate between 10% and 20% can be regarded as
acceptable. This means that the resection rate for benign
disease in the NELSON lung cancer screening trials was too
high but after adjustment for clinical relevant disease (17%),
within the acceptable range.
Question was, whether a preoperative PET scan could
help to reduce the resection rate for benign lesions after a
negative nonsurgical workup. In the scenario that PET neg-
ative and indeterminate test results are regarded as PET
negative (Table 4) instead of 137 subjects, only 92 partici-
pants would have been operated with a reduction in the
resection rate for benign disease from 23% (31/137) to 8%
(11/137). If PET positive and PET indeterminates are taken
together (Table 4), the resection rate for benign disease would
TABLE 4. Diagnostic Performance of FDG-PET during Baseline and Second Round Screening of the NELSON
Randomized Controlled Lung Cancer Screening Trial
PET Result Cancer Benign
Sensitivity
(95% CI)
Specificity
(95% CI)
PPV
(95% CI)
NPV
(95% CI)
All subjects (n  229)
Positive or indeterminate 101 27 84.2 (77.6–90.7) 75.2 (67.1–83.3) 78.9 (71.8–86.0) 81.2 (73.6–88.8)
Negative 19 82
Subjects with nodules 500 mm3
(9.6 mm) (n  159)
Positive or indeterminate 80 24 90.9 (84.9–96.9) 66.2 (55.2–77.2) 76.9 (68.8–85.0) 85.5 (76.1–94.8)
Negative 8 47
Inconclusive nonsurgical workup
(n  137)
Positive or indeterminate 89 17 84.8 (77.9–91.6) 46.9 (29.6–64.2) 84.0 (77.-0–91.0) 48.4 (30.8–66.0)
Negative 16 15
Conclusive nonsurgical workup
(n  92)
Positive or indeterminate 12 10 80.0 (59.8–100) 87.0 (79.5–94.5) 54.5 (33.7–75.4) 95.7 (91.0–100)
Negative 3 67
All subjects (n  229)
Positive 92 13 76.7 (69.1–84.2) 88.1 (82.0–94.2) 87.6 (81.3–93.9) 77.4 (70.1–84.8)
Negative or indeterminate 28 96
Subjects with nodules 500 mm3
(9.6 mm) (n  159)
Positive 73 11 83.0 (75.1–90.8) 84.5 (76.1–92.9) 86.9 (79.7–94.1) 80.0 (71.0–89.1)
Negative or indeterminate 15 60
Inconclusive nonsurgical workup
(n  137)
Positive 81 11 77.1 (69.1–85.2) 65.6 (49.2–82.1) 88.0 (81.4–94.7) 46.7 (32.1–61.4)
Negative or indeterminate 24 21
Conclusive nonsurgical workup
(n  92)
Positive 11 2 73.3 (51.0–95.7) 97.4 (93.8–100) 84.6 (65.0–100) 94.9 (90.1–99.8)
Negative or indeterminate 4 75
PPV, positive predictive value; NPV, negative predictive value; CI, confidence interval; FDG-PET, (18)F-fluorodeoxyglucose-positron emission
tomography.
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have been 12% (17/137). Thus, a preoperative PET can help
to reduce the resection rate for benign disease but at the
expense of missing, respectively, 24 and 16 lung cancer
cases, which is unacceptable due to the low NPV of PET in
this setting, and should not be recommended. Also, other
investigators demonstrated that lung cancer can show faint
FDG uptake, which should not be neglected.31 In small
malignant pulmonary nodules less than 20 mm and less than
10 mm, 19% and 20% was PET negative, respectively.32,33
In contrast, the role of PET after a conclusive nonsur-
gical workup was evident; the resection rate for benign
disease in this group decreased from 84% (78/93) to 12%
(11/93) at the expense of only 3% (3/92) additional missed
cancers because of the very high NPV of 96% (Table 4).
Thus, after a conclusive nonsurgical workup, the resection
rate for benign disease can be decreased by 72%.
Limitation of our study was that there was no standard-
ized FDG-PET protocol, which could have been a potential
source of bias, although it reflects our daily practice of
evaluating pulmonary nodules. Differences in FDG-uptake
and imaging time may have led to differences in FDG-uptake
in tumor to background ratio and, thus, may have influenced
the PET results. No second reading was done, which may
have led diminished the reproducibility. Another limitation of
our study is that, we were not able to calculate SUVs because
there were no national standards available for comparison
between the institutes at the time of the study.15 Nevertheless,
several authors recommended qualitative analysis over quan-
titative analysis31,34,35 because no improvement in accuracy
was observed by semiquantitative approaches over visual
analysis of pulmonary nodules 10 to 30 mm31 or 7 mm.35
The same was found for nodules with a SUV less than 2.5.34
The classical threshold of SUV 2.5 may be inappropriate for
diagnosing malignancies with low FDG-uptake,36,37 and a
lower cutoff of 1.5 to 2 might be more appropriate.4,19
Another important limitation of the study is that, although the
PET was made for staging purposes in case the nodule turned
out to be malignant at surgery, the investigators were not
blinded to the outcome of the PET result with respect to the
uptake by the suspicious nodule. Therefore, outcome of
the nonsurgical workup (conclusive or inconclusive) may
have been influenced by the outcome of the PET result. Our
nodule management strategy was based on VDT and nodule
size only and did not include the use of transthoracic needle
biopsies (7). This should not be regarded as limitation of this
study but rather the result of our NELSON nodule manage-
ment strategy based on which the workup of nodules was
performed. In conclusion, a preoperative PET scan in partic-
ipants with an inconclusive nonsurgical workup is not rec-
ommended because of the very low NPV, but after a conclu-
sive nonsurgical workup, the resection rate for benign lesions
can be decreased by 72%.
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